Who We Are
Living our mission
At CRISPR Therapeutics, our aim is to find cures for people suffering from serious diseases through transformative gene-based medicines. We innovate for the sake of patients and families.
Creating an impact
The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. This CRISPR/Cas9 therapy is now approved in some countries for certain eligible people living with sickle cell disease or transfusion-dependent beta thalassemia. And we have only begun to see the applications for CRISPR technology. We believe this once-in-a-generation breakthrough will make an impact for generations to come.
Guided by our people
From our bench scientists to our development team to our executive leaders, we see each team member as a pioneer of what’s next for our organization and the field of medicine as a whole.
Do you believe you have what it takes to join us on this journey? Are you motivated by the prospect of making a difference in people’s lives? Let’s see if we can find a fit.
A History of Innovation
1905-1910
The word “gene” began to be used and the field of genetics gained momentum.
1953
DNA’s double-helix structure is discovered, giving rise to modern molecular biology.
2003
Scientists read the entire human genome for the first time, marking the completion of The Human Genome Project.
2012
Emmanuelle Charpentier, Ph.D. and Jennifer Doudna, Ph.D. and others author historic scientific paper on CRISPR/Cas9 as a gene editing tool.
2013
CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics.
2014-2018
Advances programs and releases pioneering preclinical data across hematology, immuno-oncology and regenerative medicine.
2019
Releases first-ever patient data on a CRISPR-based investigational therapy, later published in The New England Journal of Medicine.
2019-2023
Announces results of ongoing clinical trials supporting the continued advancement of CRISPR-based investigational therapy.
2020
Charpentier and Doudna receive Nobel Prize in Chemistry for their groundbreaking work on the CRISPR/Cas9 system; announces first clinical data on an investigational CRISPR edited allogeneic CAR T cell therapy.
2021
Opens the doors to its own manufacturing facility in Framingham, Massachusetts.
2022
Opens the doors to new R&D Headquarters in Boston; receives International Society for Pharmaceutical Engineering (ISPEE) 2022 Facility of the Year Award (FOYA) in the Innovation Category for our Framingham manufacturing facility; CRISPR-X team forms in both Boston and San Francisco.
2023
Historic approval in the United States, Great Britain and Bahrain for the first-ever CRISPR-based therapy, in collaboration with Vertex Pharmaceuticals Incorporated.
* In collaboration with Vertex Pharmaceuticals Incorporated, we’ve co-developed a gene-editing treatment that is currently approved in some countries for certain eligible people living with sickle cell disease or transfusion-dependent beta thalassemia. This treatment may not be approved and/or licensed in all countries where this website is accessible.
Where We Work
Home to our R&D headquarters, where we continually innovate and push the limits of science and technology.
Boston, MA
Home to our R&D headquarters, where we continually innovate and push the limits of science and technology.
Where we’ve built our state-of-the-art, award-winning manufacturing facility.*
Framingham, MA
Where we’ve built our state-of-the-art, award-winning manufacturing facility.*
San Francisco, CA
Our growing R&D hub. Here we focus on the most advanced gene editing and delivery technologies of the future.
Zug, Switzerland
Our global headquarters location, where we first made our mark as a cutting-edge biotech company.
*International Society for Pharmaceutical Engineering (ISPE) 2022 Facility of the Year Award (FOYA) in the Innovation category for our flexible, digitally-enabled and innovative facility design.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.